Literature DB >> 33210370

Exceptional Survival Among Kentucky Stage IV Non-small Cell Lung Cancer Patients: Appalachian Versus Non-Appalachian Populations.

Vira Pravosud1, Nathan L Vanderford2,3, Bin Huang4,3, Thomas C Tucker1,3, Susanne M Arnold5,3.   

Abstract

PURPOSE: To determine differences in exceptional survival (ES)-survival of 5 years or more past diagnosis-between stage IV non-small cell lung cancer (NSCLC) patients residing in the Appalachian versus non-Appalachian regions of Kentucky.
METHODS: This was a population-based, retrospective case-control study of Kentucky patients, diagnosed with stage IV NSCLC between January 1, 2000, and December 31, 2011. The data were drawn from the Kentucky Cancer Registry.
FINDINGS: Findings from the multivariable logistic regression revealed no significant differences in the odds of ES between patients who resided in Appalachian versus non-Appalachian Kentucky. Being female and undergoing surgery only as the first course of treatment were associated with higher odds of ES. Increasing age, unspecified histology, having poorly differentiated or undifferentiated carcinomas, and receiving radiation therapy only as the first course of treatment were associated with decreased odds of ES.
CONCLUSION: Differences in the odds of ES among stage IV NSCLC patients were not related to residence in Appalachian versus non-Appalachian Kentucky. ES was associated with other nongenetic and treatment factors that warrant further investigations.
© 2020 National Rural Health Association.

Entities:  

Keywords:  Appalachia; Charlson comorbidity index (CCI); exceptional survival; rural; stage IV non-small cell lung cancer (NSCLC)

Mesh:

Year:  2020        PMID: 33210370      PMCID: PMC9106424          DOI: 10.1111/jrh.12537

Source DB:  PubMed          Journal:  J Rural Health        ISSN: 0890-765X            Impact factor:   5.667


  56 in total

Review 1.  The surveillance, epidemiology, and end results program: a national resource.

Authors:  B F Hankey; L A Ries; B K Edwards
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-12       Impact factor: 4.254

2.  Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules.

Authors:  S C Erridge; M N Gaze; A Price; C G Kelly; G R Kerr; A Cull; R H MacDougall; G C W Howard; V J Cowie; A Gregor
Journal:  Clin Oncol (R Coll Radiol)       Date:  2005-02       Impact factor: 4.126

Review 3.  Social support and quality of life among lung cancer patients: a systematic review.

Authors:  Aleksandra Luszczynska; Izabela Pawlowska; Roman Cieslak; Nina Knoll; Urte Scholz
Journal:  Psychooncology       Date:  2012-10-25       Impact factor: 3.894

4.  Survival after resection for primary lung cancer: a population based study of 3211 resected patients.

Authors:  T-E Strand; H Rostad; B Møller; J Norstein
Journal:  Thorax       Date:  2006-04-06       Impact factor: 9.139

5.  The burden of lung cancer in Kentucky.

Authors:  Claudia Hopenhayn; Todd M Jenkins; Joe Petrik
Journal:  J Ky Med Assoc       Date:  2003-01

Review 6.  Lung cancer care: the impact of facilities and area measures.

Authors:  Christopher S Lathan
Journal:  Transl Lung Cancer Res       Date:  2015-08

Review 7.  Non-small cell lung cancer in the elderly.

Authors:  Paris D Makrantonakis; Eleni Galani; Peter G Harper
Journal:  Oncologist       Date:  2004

8.  The impact of symptoms, coping capacity, and social support on quality of life experience over time in patients with lung cancer.

Authors:  Ingela Henoch; Bengt Bergman; Marianne Gustafsson; Fannie Gaston-Johansson; Ella Danielson
Journal:  J Pain Symptom Manage       Date:  2007-07-05       Impact factor: 3.612

9.  Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.

Authors:  E Rapp; J L Pater; A Willan; Y Cormier; N Murray; W K Evans; D I Hodson; D A Clark; R Feld; A M Arnold
Journal:  J Clin Oncol       Date:  1988-04       Impact factor: 44.544

10.  Histology matters: individualizing treatment in non-small cell lung cancer.

Authors:  Joel W Neal
Journal:  Oncologist       Date:  2010-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.